Arginine Vasopressin Immunoreactivity is Decreased in the Hypothalamic Suprachiasmatic Nucleus of Subjects with Suprasellar Tumors

• Published in: Brain pathology (Zurich, Switzerland) Vol. 23; no. 4; pp. 440 - 444
• Main Authors: Borgers, Anke J., Fliers, Eric, Siljee, Jacqueline E., Swaab, Dick F., Van Someren, Eus J. W., Bisschop, Peter H., Alkemade, Anneke
• Format: Journal Article
• Language: English
• Published: Switzerland Blackwell Publishing Ltd 01.07.2013; John Wiley & Sons, Inc; John Wiley and Sons Inc
• Subjects: Aged; Aged, 80 and over; anterior hypothalamus; Arginine Vasopressin - metabolism; Defects; Eyes & eyesight; Female; Gene Expression Regulation, Neoplastic - physiology; Humans; Male; Middle Aged; Perceptual Disorders - etiology; Pituitary Neoplasms - complications; Pituitary Neoplasms - pathology; Postmortem Changes; sleep; suprachiasmatic nucleus; Suprachiasmatic Nucleus - metabolism; suprasellar tumor; Tumors; Vasoactive Intestinal Peptide - metabolism; vasopressin; Visual Fields - physiology
• ISSN: 1015-6305; 1750-3639; 1750-3639
• DOI: 10.1111/bpa.12016

Suprasellar tumors with compression of the optic chiasm are associated with an impaired sleep–wake rhythm. We hypothesized that this reflects a disorder of the biological clock of the human brain, the suprachiasmatic nucleus (SCN), which is located just above the optic chiasm. In order to test this hypothesis, we investigated the expression of two key neuropeptides of the SCN, that is, arginine vasopressin (AVP) and vasoactive intestinal peptide (VIP), as assessed by quantitative immunocytochemistry in post‐mortem hypothalamic tissue of patients with a suprasellar tumor inducing permanent visual field defects. Post‐mortem hypothalamic tissue of 5 patients with a suprasellar tumor inducing permanent visual field defects (acromegaly n = 2, nonfunctioning macro‐adenoma n = 1, macroprolactinoma n = 1, infundibular metastasis of a colorectal adenocarcinoma n = 1) and 15 age‐ and gender‐matched controls was obtained from the Netherlands Brain Bank. Total AVP immunoreactivity in the SCN was lower in patients with a suprasellar tumor than in controls (P = 0.03). By contrast, total VIP immunoreactivity was not different between patients and controls (P = 0.44). Suprasellar tumors leading to permanent visual field defects are associated with reduced AVP, but not VIP immunoreactivity, in the SCN. These findings raise the possibility that selective impairment of the SCN contributes to sleep–wake disturbances in these patients.